Sign In
Buy BNTX
$89.59
+1.14 (+1.29%)
At Close: Jun 04, 2026
7 Safe Stocks to Buy for an Economic Downward Spiral
04:35pm, Tuesday, 16'th May 2023
For those that want to stay in the market during these ambiguous times, investors should consider safe stocks to buy. Basically, as Wall Street rotates away from risk-on assets, companies exclusively
BioNTech: Hold Out For More Data (Rating Downgrade)
08:00am, Friday, 12'th May 2023
Since initial coverage, BioNTech stock has lost $6 billion in value. BNTX's first quarter revenues were $5.6 billion less than 2022.
As COVID public health emergency ends, ‘whack-a-mole' virus won't be easy to track
02:30pm, Wednesday, 10'th May 2023
As the U.S. COVID-19 public health emergency comes to an end on Thursday, the fight against COVID goes on–-and some new challenges begin for those who hope to keep the virus at bay.
BioNTech braces for weak Q2 as Covid vaccine demand subsides
01:01pm, Wednesday, 10'th May 2023
BioNTech is facing a weak second quarter of 2023 as demand for Covid vaccines wane throughout the warmer summer months. Analysts at Canaccord have noted the drug maker's “seasonal administration pat
BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations
09:18am, Monday, 08'th May 2023
BioNTech handily beat first-quarter profit expectations and delivered better-than-expected sales, leading BNTX stock to jump Monday. The post BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat
BioNTech reports strong 1Q earnings; expands focus beyond Covid-19 vaccines
08:53am, Monday, 08'th May 2023
Covid-19 vaccine maker BioNTech SE has reported better-than-expected earnings, exceeding analyst estimates for the first quarter. Sales of €1.28 billion ($1.4 billion) surpassed the €1.1 billion a
BioNTech Revenue Falls. Why the Stock Is Climbing Anyway.
07:38am, Monday, 08'th May 2023
BioNTech's first-quarter revenue falls from a year earlier as demand for Covid-19 vaccines wanes but still tops analysts' estimates.
BioNTech's stock jumps 4.3% premarket after earnings fall but top estimates
07:09am, Monday, 08'th May 2023
BioNTEch SE's stock BNTX rose 4.3% in premarket trade Monday, after the German biotech posted far stronger-than-expected first-quarter earnings, even as profit and revenue tumbled on lower demand for
Earnings Previews: BioNTech, Tyson Foods, Warner Bros Discovery
10:14am, Thursday, 04'th May 2023
In the first half-hour of Thursday's trading, the Dow Jones industrials were down 0.38%, the S&P 500 traded 0.35% and the Nasdaq 0.31% lower.
FDA authorizes Pfizer-BioNTech booster for young kids with compromised immune systems
04:38pm, Friday, 28'th Apr 2023
The U.S. Food and Drug Administration late Friday authorized Pfizer Inc. PFE and BioNTech SE BNTX COVID-19 bivalent vaccine for immunocompromised children. The shot, which would be a fourth dose in mo
Top Biotech Stocks For Q2 2023: First Gem Is BioNTech
02:01am, Tuesday, 25'th Apr 2023
Top Biotech Stocks For Q2 2023: First Gem Is BioNTech.
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
06:45am, Monday, 24'th Apr 2023
MAINZ, Germany , April 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8th,
7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value
07:32pm, Wednesday, 19'th Apr 2023
While the concept of acquiring low-PE ratio blue-chip stocks (that is, industry-leading stalwarts that feature low price-earnings ratios relative to their sectors) appeals on paper, investors need to
FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations
09:55am, Wednesday, 19'th Apr 2023
To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.
BioNTech FY22 Earnings Review - 5 Questions Answered After Today's Results
07:47pm, Monday, 27'th Mar 2023
BioNTech announced its Q422 and FY22 earnings today, and also provided FY23 guidance. Revenues were ~$18.7bn, thanks to its share of revenues from sales of the Comirnaty COVID vaccine it co-developed
